Stability of Serum Eye Drops After Storage of 6 Months

Fischer, Kai R.; Opitz, Andreas; Böeck, Markus; Geerling, Gerd

doi:10.1097/ico.0b013e3182542085

Cited by 30 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This decision is based on the significant effect that 50% AS has shown in several studies [1, 14, 50] and on the hypothesis that at higher concentrations some components can become harmful. In fact, the concentration of biologically active molecules is different in serum and tear fluids.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

Semeraro

Forbice

Braga

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Purpose. This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy. Methods. We analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids. Results. We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred. Conclusions. Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

Semeraro

Forbice

Braga

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The amount of the substances in the eye drops should be maintained consistently during storage for the therapeutic effect of the ASEDs. Recently, a study reported that when unopened bottles were stored at −20°C, the concentrations of substances in ASEDs were not significantly changed for up to 6 months . In England and Wales, because ASEDs are made from the full donation (approx.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a study reported that when unopened bottles were stored at −20°C, the concentrations of substances in ASEDs were not significantly changed for up to 6 months. 34 In England and Wales, because ASEDs are made from the full donation (approx. 470 mL) of 1 blood unit, 16,17 a 5-or 6-month supply of ASEDs can be made, and a shelf life of 6 months has been adopted for unopened dropper bottles.…”

Section: Discussionmentioning

confidence: 99%

Proposal of standardized guidelines for the production and quality control of autologous serum eye drops in Korea: based on a nationwide survey

et al. 2014

View full text Add to dashboard Cite

Based on an analysis of the survey results and a review of the standard operating procedures and protocols for ASEDs used in Japan, Germany, England and Wales, and the United States, we proposed standardized guidelines for the production and QC of ASEDs in Korea. ASEDs are not cell therapy products in the strictest sense. However, because eye drops are composed of serum isolated from blood and are used in patients, we consider ASEDs to be the basis for cell therapy products. Therefore, ASEDs should be produced and stored according to standardized guidelines based on the Good Manufacturing Practice guidelines.

show abstract

“…DMSO is a relatively stable protective agent to maintain the integrity of corneal cells, while sucrose molecules act as buffers in corneal protection, and ChS improves CEC activity in cryopreservation [98]. DMSO began to be treated as a tissue preservative to preserve cultured rabbit CECs by Smith [99]. Shortly thereafter, Mueller injected a preservation solution containing DMSO into the anterior chamber of an eyeball, placing the eyeball in a preservation solution containing glycerol.…”

Section: Corneal Cryopreservation Technologymentioning

confidence: 99%

Cryopreservation in Ophthalmology

Shao¹,

Chen²,

Zhou³

et al. 2020

Cryopreservation - Current Advances and Evaluations

View full text Add to dashboard Cite

Amniotic membranes (AMs) and corneas are critical materials in ocular surface reconstruction. AM has specific structures (e.g., basement and two types of cells with stemness characteristics: amniotic epithelial cells and amniotic mesenchymal cells), which contribute to its attractive physical and biological properties that make it fundamental to clinical application. The corneal endothelial cell is a vital part of the cornea, which can influence postoperative vision directly. However, widespread use of fresh AM and cornea has been limited due to their short use span and safety concerns. To overcome these concerns, different preservation methods have been introduced. Cryopreservation is distinguished from many preservation methods for its attractive advantages of prolonged use span, optimally retained tissue structure, and minimized infection risk. This review will focus on recent advances of cryopreserved AM and cornea, including different cryopreservation methods and their indications in ophthalmology.

show abstract

Stability of Serum Eye Drops After Storage of 6 Months

Cited by 30 publications

References 15 publications

Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

Proposal of standardized guidelines for the production and quality control of autologous serum eye drops in Korea: based on a nationwide survey

Cryopreservation in Ophthalmology

Contact Info

Product

Resources

About